Cambridge, Mass. – November 10, 2015 – Nimbus Therapeutics, a biotechnology company focused on harnessing the power of computational chemistry to design breakthroughs for serious, underserved human diseases, today announced further scientific progress on its core programs that are being presented at two key scientific meetings.
“Following our recent announcement that we have partnered our IRAK4 program with Genentech, we are pleased to report exciting progress on our Tyk2 and ACC programs that we are presenting at meetings of the ACR (American College of Rheumatology) and AASLD (American Association for the Study of Liver Diseases) this week in San Francisco,” said Donald Nicholson, Ph.D., Chief Executive Officer of Nimbus Therapeutics. “In addition, our ongoing Phase 1b studies with NDI-010976, an allosteric ACC inhibitor for the treatment of NASH (non-alcoholic steatohepatitis), are looking very promising, and we anticipate sharing that data with the scientific and medical community as we embark on Phase 2 next year,” Dr. Nicholson said.
At the ACR meeting, Nimbus shared data on its highly selective Tyk2 inhibitors (abstract #1943; presented Nov. 9). Compelling human genomic evidence suggests that Tyk2 inhibitors should be of value for the treatment of inflammatory and auto-immune disorders, such as rheumatoid arthritis, lupus and others. At the AASLD meeting, Nimbus will present two posters that are collaborations with scientists from the Massachusetts General Hospital; one demonstrating the efficacy of liver-targeted allosteric inhibitors of ACC (acetyl-CoA carboxylase) in animal models of metabolic disorders including NASH (abstract #957; presenting Nov. 15), and another that demonstrates the efficacy of these ACC inhibitors in animal models of liver cancer (HCC, hepatocellular carcinoma) including benefits when combined with sorafenib, the current clinical standard of care for treating HCC (abstract #1938; presenting Nov. 17).
American College of Rheumatology (ACR) Annual Meeting
Nov. 6-11, 2015; San Francisco, Calif.
Poster Title: Potent and Selective Tyk2 Inhibitors Block Th1- and Th17- Mediated Immune Responses and Reduce Disease Progression in Rodent Models of Delayed-Type Hypersensitivity and Psoriasis
Presentation Date and Time: Monday, Nov. 9, 2015; 9 a.m. – 11 a.m.
Abstract #1943, Poster Session I
American Association for the Study of Liver Diseases (AASLD) Liver Meeting
Nov. 13-17, 2015; San Francisco, Calif.
Poster Title: Liver-Directed Allosteric Inhibitors of Acetyl-CoA Carboxylase Reduce Hepatic Steatosis and Improve Dyslipidemia in Diet-Induced Obese Rat Models and Reduce Inflammation and Fibrosis in a Cirrhotic Rat Model
Presentation Date and Time: Sunday, Nov. 15, 2015; 8 a.m. – 5 p.m.
Abstract #957, Poster Session II
Poster Title: Liver Selective Acetyl-CoA Carboxylase Inhibitor ND-654 Improves Sorafenib Efficacy in the Treatment of Hepatocellular Carcinoma in Cirrhotic Rats
Presentation Date and Time: Tuesday, Nov. 17, 2015; 8 a.m. – Noon
Abstract #1938, Poster Session IV
Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (U.S.). It is pioneering the application of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The Company works on difficult and valuable targets across the three closely related fields of immunology, metabolism, and oncology. Nimbus’ unique approach and technological prowess fuel the Company’s ability to rapidly tackle targets that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry. Nimbus’ most advanced program, an allosteric inhibitor of acetyl-CoA carboxylase (ACC) for the treatment of non-alcoholic steatohepatitis (NASH), is currently in Phase 1 clinical testing. To learn more, please visit www.nimbustx.com.